Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$650K Buy
5,501
+404
+8% +$46.6K 0.02% 402
2026
Q1
$609K Buy
5,097
+156
+3% +$20.5K 0.02% 417
2025
Q4
$673K Buy
4,941
+271
+6% +$39K 0.02% 350
2025
Q3
$689K Buy
4,670
+2,548
+120% +$353K 0.02% 358
2025
Q2
$275K Buy
2,122
+67
+3% +$8.11K 0.01% 530
2025
Q1
$245K Buy
+2,055
New +$255K 0.01% 528
2022
Q3
Sell
-189
Closed -$15K 1147
2022
Q2
$15K Buy
+189
New +$15.6K ﹤0.01% 893
2021
Q4
Sell
-338
Closed -$42K 921
2021
Q3
$42K Buy
338
+1
+0.3% +$129 ﹤0.01% 617
2021
Q2
$40K Buy
337
+78
+30% +$8.91K ﹤0.01% 606
2021
Q1
$27K Buy
259
+37
+17% +$3.75K ﹤0.01% 619
2020
Q4
$23K Buy
222
+12
+6% +$1.13K ﹤0.01% 591
2020
Q3
$18K Buy
210
+173
+468% +$13.5K ﹤0.01% 574
2020
Q2
$2K Buy
37
+29
+363% +$1.91K ﹤0.01% 775
2020
Q1
$1K Sell
8
-41
-84% -$3.23K ﹤0.01% 764
2019
Q4
$4K Sell
49
-49
-50% -$3.81K ﹤0.01% 609
2019
Q3
$8K Sell
98
-68
-41% -$5.34K ﹤0.01% 507
2019
Q2
$14K Buy
166
+126
+315% +$10K ﹤0.01% 439
2019
Q1
$3K Buy
+40
New +$2.92K ﹤0.01% 660

Other funds holding XYL

CX Institutional's XYL Position: Q2 2026 in Review

CX Institutional increased its Xylem (XYL) stake by 7.9% in Q2 2026, buying an estimated $46.6K and bringing the position to 5,501 shares worth $650K. The position accounts for 0.02% of the portfolio, ranked #402.

CX Institutional first reported a position in XYL in Q1 2019 and has held it in 18 quarters since. The position peaked at $689K in Q3 2025. 1,093 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • CX Institutional held 5,501 shares of Xylem worth $650K as of Q2 2026.
  • CX Institutional bought 404 Xylem shares in Q2 2026, an estimated $46.6K.
  • Xylem made up 0.02% of CX Institutional's portfolio in Q2 2026, its #402 holding.
  • CX Institutional first reported a position in Xylem in Q1 2019 and has held it in 18 quarters since.
  • CX Institutional's Xylem position peaked at $689K in Q3 2025.
  • 1,093 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.